Plasma Levels of Asymmetric Dimethylarginine in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background: Asymmetric dimethylarginine (ADMA) is a marker of endothelial dysfunction and a new independent risk factor for adverse cerebrovascular events in small vessel disease. Conversely, L-arginine (LARG) may have a protective role. Methods: To assess ADMA, LARG levels and LARG/ADMA ratio in 16 patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and normal controls, and to look for possible correlations with white matter changes. Plasma levels of ADMA and LARG were assayed by high-performance liquid chromatography in all subjects. The overall T 1 and T 2 lesion load was obtained from brain MRI of patients with CADASIL. Results: ADMA plasma concentrations (1.5 ± 2.0 µ M) were significantly higher (p < 0.05) in CADASIL patients than in controls (0.35 ± 0.075 µ M). Analyzing only CADASIL subjects, an inverse borderline-significant correlation was found between LARG/ADMA (190 ± 20) and T 2-weighted lesion volumes (57.9 ± 46.5; r = –0.578, p = 0.024). Conclusion: Our results may indicate the possible coexistence of endothelial dysfunction in CADASIL patients, broadening the range of potentially pathogenetic mechanisms in this disease and providing insights for future therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“White matter lesions and lacunar strokes are associated with increases in circulating levels of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) (Notsu et al., 2009; Pikula et al., 2009; Rufa et al., 2008).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Rufa et al., 2008
Citations
Cites
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia
Joutel, A., Corpechot, C., Ducros, A., Vahedi, K., Chabriat, H., Mouton, P., Alamowitch, S., Domenga, V., Cécillion, M., Maréchal, E., et al. (1996) · Nature · doi:10.1038/383707a0 · Cited by 2,068 · cited 1×
“Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited form of small vessel disease due to mutations in the Notch3 gene [”
BackgroundBöger, R. H., Bode-Böger, S. M., Thiele, W., Junker, W., Alexander, K., & Frölich, J. C. (1997) · Circulation · doi:10.1161/01.cir.95.8.2068 · Cited by 490 · cited 1×
“Emerging evidence indicates that endothelial dysfunction, resulting from impaired bioavailability of nitric oxide (NO), plays a pivotal role in the atherothrombotic process. Endothelial-derived NO production is reduced in subjects with cardiovascular risk factors [”
BackgroundTeerlink, T., Nijveldt, R. J., de Jong, S., & van Leeuwen, P. A. M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5575 · Cited by 417
Kielstein, J. T., Impraim, B., Simmel, S., Bode-Böger, S. M., Tsikas, D., Frölich, J. C., Hoeper, M. M., Haller, H., & Fliser, D. (2004) · Circulation · doi:10.1161/01.cir.0000105764.22626.b1 · Cited by 401 · cited 1×
“and elevated levels of amino acid asymmetric dimethylarginine (ADMA) have been found to be significantly associated with the risk of adverse vascular events [”
BackgroundMechanisms of homocysteine‐induced atherothrombosis
LENTZ, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01364.x · Cited by 363
Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction
Hassan, A. (2004) · Brain · doi:10.1093/brain/awh023 · Cited by 338
Tran, C. T. L., Leiper, J. M., & Vallance, P. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00032-1 · Cited by 314
van Waesberghe, J. H., van Walderveen, M. A. A., Castelijns, J. A., Scheltens, P., Nijeholt, G. J. L. À., Polman, C. H., & Barkhof, F. (1998) · American Journal of Neuroradiology · Cited by 311
ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans
Kielstein, J. T., Donnerstag, F., Gasper, S., Menne, J., Kielstein, A., Martens-Lobenhoffer, J., Scalera, F., Cooke, J. P., Fliser, D., & Bode-Böger, S. M. (2006) · Stroke · doi:10.1161/01.str.0000231640.32543.11 · Cited by 217
The influence of genetic and cardiovascular risk factors on the CADASIL phenotype
Singhal, S. (2004) · Brain · doi:10.1093/brain/awh223 · Cited by 217 · cited 1×
“Homocysteine has been shown to induce ADMA accumulation by inhibiting the activity of endothelial DDAH as well as indirectly by increasing oxidative stress and concentration of proinflammatory cytokines [ ,”
Background
Research works printed but not linked: 1
- 10.1111%2Fj.1365-2990.1997.tb01210.x · doi:10.1111/j.1365-2990.1997.tb01210.x
Cited by
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
“White matter lesions and lacunar strokes are associated with increases in circulating levels of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) (Notsu et al., 2009; Pikula et al., 2009; Rufa et al., 2008).”
Cuadrado-Godia, E., Dwivedi, P., Sharma, S., Ois Santiago, A., Roquer Gonzalez, J., Balcells, M., Laird, J., Turk, M., Suri, H. S., Nicolaides, A., et al. (2018) · Journal of Stroke · doi:10.5853/jos.2017.02922 · Cited by 286
Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review
Poggesi, A., Pasi, M., Pescini, F., Pantoni, L., & Inzitari, D. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.116 · Cited by 253
“ADMA levels were significantly increased in 14 CADASIL patients compared with 22 healthy controls.(86) Similarly, in 59 CADASIL there were higher HCY levels in comparison with 14 non-CADASIL patients with stroke or transient ischemic attack, both in the fasting state and after methionine challenge.”
ResultMolecular biomarkers for vascular cognitive impairment and dementia
Hosoki, S., Hansra, G. K., Jayasena, T., Poljak, A., Mather, K. A., Catts, V. S., Rust, R., Sagare, A. P., Kovacic, J. C., Brodtmann, A. G., et al. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00884-1 · Cited by 185
“Endothelial dysfunction: atherosclerosis and arteriolosclerosis increase production of asymmetric dimethylarginine (ADMA), which inhibits endothelial nitric oxide synthase (eNOS), thereby reducing endothelial nitric oxide (NO) production (1) and contributing to dysfunction of vascular autoregulation.”
BackgroundInfluentialStevenson, S. F., Doubal, F. N., Shuler, K., & Wardlaw, J. M. (2010) · Stroke · doi:10.1161/strokeaha.109.569855 · Cited by 112
Endothelial Cells and Human Cerebral Small Vessel Disease
Hainsworth, A. H., Oommen, A. T., & Bridges, L. (2014) · Brain Pathology · doi:10.1111/bpa.12224 · Cited by 114
“Clinical studies of CADASIL support the notion of a relatively intact endothelium in the presence of SVD vasculopathy (62, 71, 72, 78).”
BackgroundAsymmetric Dimethyarginine as Marker and Mediator in Ischemic Stroke
Chen, S., Li, N., Deb‐Chatterji, M., Dong, Q., Kielstein, J. T., Weißenborn, K., & Worthmann, H. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215983 · Cited by 90
“(CADASIL) an inverse correlation was found between the L-arginine/ADMA ratio in plasma and T2 weighted lesion volumes in MRI, indicating endothelial dysfunction in these patients [79].”
BackgroundCADASIL: Experimental Insights From Animal Models
Ayata, C. (2010) · Stroke · doi:10.1161/strokeaha.110.595207 · Cited by 75
Kielstein, H., Suntharalingam, M., Perthel, R., Song, R., Schneider, S. M., Martens-Lobenhoffer, J., Jäger, K., Bode-Böger, S. M., & Kielstein, J. T. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv253 · Cited by 58
“Since then, ADMAhas been shown to be increased in Alzheimers patients [7] and inherited forms of cerebral arteriopathy leading to subcortical infarcts and leucoencephalopathy [8].”
BackgroundArginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications
Große, G. M., Schwedhelm, E., Worthmann, H., & Choe, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051798 · Cited by 57
Epigenetic and integrative cross-omics analyses of cerebral white matter hyperintensities on MRI
Yang, Y., Knol, M. J., Wang, R., Mishra, A., Liu, D., Luciano, M., Teumer, A., Armstrong, N. J., Bis, J. C., Jhun, M. A., et al. (2022) · Brain · doi:10.1093/brain/awac290 · Cited by 58
Janes, F., Cifù, A., Pessa, M. E., Domenis, R., Gigli, G. L., Sanvilli, N., Nilo, A., Garbo, R., Curcio, F., Giacomello, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50778-w · Cited by 42
The clinical manifestations and pathophysiology of cerebral small vessel disease
Zhang, A.-J., Yu, X., & Wang, M. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-1210-y · Cited by 44
Pescini, F., Cesari, F., Giusti, B., Sarti, C., Zicari, E., Bianchi, S., Dotti, M. T., Federico, A., Balestrino, M., Enrico, A., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.563726 · Cited by 45
Self-citationSimultaneous Impairment of Intracranial and Peripheral Artery Vasoreactivity in CADASIL Patients
Fujiwara, Y., Mizuno, T., Okuyama, C., Nagakane, Y., Watanabe-Hosomi, A., Kondo, M., Kuriyama, N., Tokuda, T., Matsushima, S., Nishimura, T., et al. (2011) · Cerebrovascular Diseases · doi:10.1159/000334185 · Cited by 34
Molnár, T., Pusch, G., Papp, V., Fehér, G., Szapáry, L. B., Biri, B., Nagy, L., Kéki, S., & Illés, Z. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.05.002 · Cited by 30
Impaired vasoreactivity in mildly disabled CADASIL patients
Campolo, J., Maria, R. D., Frontali, M., Taroni, F., Inzitari, D., Federico, A., Romano, S., Puca, E., Mariotti, C., Tomasello, C., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300080 · Cited by 21
Self-citationPescini, F., Donnini, I., Cesari, F., Nannucci, S., Valenti, R., Rinnoci, V., Poggesi, A., Gori, A. M., Giusti, B., Rogolino, A. A., et al. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.10.027 · Cited by 19
Self-citationMaria, R. D., Campolo, J., Frontali, M., Taroni, F., Federico, A., Inzitari, D., Tavani, A., Romano, S., Puca, E., Orzi, F., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.005937 · Cited by 17
Self-citationPescini, F., & Abbate, R. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.017 · Cited by 4
Suntharalingam, M., Kielstein, H., Rong, S., Perthel, R., Bode‐Böger, S. M., & Kielstein, J. T. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv174.15 · Cited by 4
“Since then, ADMAhas been shown to be increased in Alzheimers patients [7] and inherited forms of cerebral arteriopathy leading to subcortical infarcts and leucoencephalopathy [8].”
BackgroundZhao, Y., Lu, Y., Wang, F., Wang, Y., Li, Y., Sun, R., Shang, J., Jiang, C. Q., & Zhang, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1573052 · Cited by 6
Carluccio, M. A., Donato, I. D., Pescini, F., Battaglini, M., Bianchi, S., Valenti, R., Nannucci, S., Franci, B., Stromillo, M. L., Stefano, N. D., et al. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2900-2 · Cited by 4
Self-citationBiomarker advancements in cerebral small vessel disease: An overview
Luo, W., Cao, C., Li, W., Wei, T., Zhao, Z., Wang, G., Li, X., Li, Y., & Liu, B. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01329 · Cited by 4
“In CADASIL, a genetic form of CSVD, researchers have reported significantly higher ADMA levels in patients compared to controls (Rufa et al., 2008).”
Biomarkers of endothelial dysfunction in cerebral small vessel disease
Tanrıverdi, U., Gurel, C. B., Ayaz, G., Ulutin, T., Arslan, S., Kızılkılıç, O., Gez, S., Gündüz, A., & İnce, B. (2024) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.28825 · Cited by 1
Current Perspectives in Post-stroke Cognitive Impairment
Federico, A., Guekht, A. B., & Brainin, M. (2013) · European Neurological Review · doi:10.17925/enr.2013.08.02.136 · Cited by 1
Self-citationFang, K., Chen, S., Wang, Y., Chen, F., Cui, M., & Dong, Q. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5339361 · Cited by 1
“Increased ADMA levels have been observed in patients with hypertension, hyperlipidemia, diabetes, atrial fi brillation, old age, and atherosclerotic burden [2 – 4], as well as in patients with acute stroke [5, 6] and chronic stroke [7, 8].”
RetractedA novel report of Cys1298Gly mutation in exon 24 of NOTCH3 gene in a Chinese family with CADASIL
Hu, J., Qian, J., Che, Z., Tang, B., Li, Y., Gong, Q., & Lu, X. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107208 · Cited by 1
Blood-Brain Barrier Permeability and Inflammation in Cerebral Small Vessel Disease
Walsh, J. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.50869 · Cited by 2
Morphometric Study of Cerebral Arterioles in CADASIL
Miao, Q. (2011) · UTUPub (University of Turku)
Neuroimaging and laboratory aspects
Pantoni, L., & Gorelick, P. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.012
Metadata
- Authors
- Rufa, A., Blardi, P., De Lalla, A., Cevenini, G., De Stefano, N., Zicari, E., Auteri, A., Federico, A., & Dotti, M. T.
- Affiliations
- University of Siena (IT)
- Venue
- Cerebrovascular Diseases
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 26
- Issue
- 6
- Pages
- 636-640
- ISSN
- 1015-9770 (ISSN-L)
- 1421-9786
- OpenAlex
- W1994769231
- Cited by
- 31
- References
- 21
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 1
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Cerebrovascular Diseases (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Cerebrovascular and genetic disorders
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- asymmetric dimethylarginine, L-arginine, CADASIL, endothelial dysfunction, cerebral small vessel disease, white matter lesions, plasma biomarkers, T2 lesion volume, L-arginine/ADMA ratio
- MeSH terms
- Receptor, Notch3, Adult, Antihypertensive Agents, Arginine, Brain, Chromatography, High Pressure Liquid, Endothelium, Vascular, Female, Humans, Hypertension, Lipids, Magnetic Resonance Imaging, Male, Middle Aged, Risk Factors, Biomarkers, CADASIL, Receptors, Notch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.